NMDAE
CMUH110-REC3-123
Phase 2 small_molecule active
Quick answer
NMDAE for Major Depressive Disorder is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Major Depressive Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active